Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mercer

Showing results (271-280 of 295) with videos related to

Pageof 30
Sort By:
Plos One|December 29, 2018
Assessing the sensitivity of the polio environmental surveillance systemSteve J Kroiss, Maiwand Ahmadzai, Jamal Ahmed, et al.
The Journal of Infectious Diseases|February 5, 2000
Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learnedS Dittmann, M Wharton, C Vitek, et al.
Vaccine|August 11, 2025
Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)Viravarn Luvira, Saranath Lawpoolsri, Weerapong Phumratanaprapin, et al.
Lancet (London, England)|February 24, 1999
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical trainingH Montgomery, P Clarkson, M Barnard, et al.
The Lancet. Infectious Diseases|March 22, 2025
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trialTsiri Agbenyega, Anne E Schuind, Samuel Adjei, et al.
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Lancet. Microbe|November 4, 2022
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsRahnuma Wahid, Laina D Mercer, Tirza De Leon, et al.
Vaccine|February 6, 2023
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized studyRahsan Erdem, Ilse De Coster, Kanchanamala Withanage, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
Pageof 30

Showing results (271-280 of 295) with videos related to

Sort By:
Pageof 30
Plos One|December 29, 2018
Assessing the sensitivity of the polio environmental surveillance systemSteve J Kroiss, Maiwand Ahmadzai, Jamal Ahmed, et al.
The Journal of Infectious Diseases|February 5, 2000
Successful control of epidemic diphtheria in the states of the Former Union of Soviet Socialist Republics: lessons learnedS Dittmann, M Wharton, C Vitek, et al.
Vaccine|August 11, 2025
Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S)Viravarn Luvira, Saranath Lawpoolsri, Weerapong Phumratanaprapin, et al.
Lancet (London, England)|February 24, 1999
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical trainingH Montgomery, P Clarkson, M Barnard, et al.
The Lancet. Infectious Diseases|March 22, 2025
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trialTsiri Agbenyega, Anne E Schuind, Samuel Adjei, et al.
Vaccines|June 25, 2026
Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai AdultsKriengkrai Prasert, Sutthichai Nakphook, Jiraphut Kittiwatanachod, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Lancet. Microbe|November 4, 2022
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trialsRahnuma Wahid, Laina D Mercer, Tirza De Leon, et al.
Vaccine|February 6, 2023
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized studyRahsan Erdem, Ilse De Coster, Kanchanamala Withanage, et al.
Vaccine|November 30, 2024
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trialVu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, et al.
Pageof 30